StockWatch
·
Q1 FY-2027 RESULTS · COSMOFIRST

Cosmo First Q1FY27: consol PAT +25% YoY on 46% revenue surge, but margins compress

PAT +25.37% YoY · revenue +45.69% · margins compressing

Q1 FY27 resultsCOSMOFIRSTCosmo First Ltd06 Aug 2026 · 3 min read
Revenue

₹1,165.54 Cr

+45.69% YoY

PAT (consolidated)

₹53.75 Cr

+25.37% YoY

Net margin

4.57%

-0.6pp YoY

EPS

₹20.71

Cosmo First's consolidated revenue rose 45.7% YoY to ₹1,165.54 Cr (+14.2% QoQ) and consolidated PAT grew 25.4% YoY to ₹53.75 Cr, with EPS at ₹20.71 versus ₹16.60 a year ago. The QoQ PAT jump of 45.6% looks dramatic but is flattered by a soft base — Q4FY26 carried a ₹7.20 Cr one-off provision (Netherlands subsidiary, unauthorised bank-transfer matter) that isn't repeated this quarter — so the YoY read is the one that matters, and on that basis profit growth trailed revenue growth by nearly 20 points, the clearest sign of margin dilution this print.

The scoreboard

Q1 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q1 FY-2027QoQYoY
Revenue₹1,165.54 Cr+14.2%+45.7%
Expenses₹1,105.85 Cr+13.7%+43.6%
PAT₹53.75 Cr+45.61%+25.37%
Net margin4.57%+1pp-0.6pp
EPS₹20.71+45.4%+24.8%

The driver sits squarely in input costs: cost of materials consumed rose 64.8% YoY (₹526.14 Cr to ₹867.36 Cr), well ahead of the 45.7% revenue increase, pulling consolidated NPM down to 4.61% from 5.20% and PBT margin to 6.07% from 6.81% a year ago. Packaging Films, still ~93% of segment revenue, saw its PBIT grow only 14.5% YoY (₹107.19 Cr to ₹122.78 Cr) against 44% segment revenue growth — margin dilution is concentrated in the core business, not the newer verticals. Petcare's segment loss widened to ₹14.84 Cr from ₹10.63 Cr even as its revenue grew 70% to ₹18.36 Cr, remaining a drag on group profitability. The one clear positive: Cosmo Plastech swung to a ₹2.46 Cr segment profit from a ₹6.63 Cr loss a year ago.

₹
669.47738.26807.05875.84944.6387705-0405-2606-1907-1508-06Q1 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹877, up 8.1% over the past month of trading.

₹ Cr
017.4334.8652.2929.56Q3 FY25rev ₹701 Cr27.1Q4 FY25rev ₹746 Cr42.87Q1 FY26rev ₹800 Cr46.69Q2 FY26rev ₹919 Cr29.5Q3 FY26rev ₹899 Cr36.91Q4 FY26rev ₹1,021 Cr
Quarterly consolidated PAT, ₹ Crore

For context: this is the highest quarterly PAT in the last 6 quarters on our records; revenue is at a 6-quarter high.

What management guided (4 FY-2026 call)
Management anticipates double-digit topline growth for the upcoming fiscal year, driven by enhanced utilization of existing capacities and growth in new business verticals like Specialty Chemicals, Rigid Packaging, and Consumer businesses. They project substantial debt reduction over the next two years, aiming to bring

— This quarter: beat

No consensus/street estimates for this print turned up in a search as of August 6, 2026 — coverage on Cosmo First appears thin for this quarter, so vsStreet is unknown rather than inferred. Against management's own May 2026 guidance of double-digit FY27 topline growth, this quarter's 45.7% YoY revenue increase is a clear beat; but the guided profitability improvement (ROCE from 11% toward 14-15%, focus on high-margin products) is not showing through yet — margins moved the wrong way this quarter. No management press-release commentary was available in our records to cross-check framing. Standalone (parent-only) PAT was nearly flat YoY at ₹29.63 Cr despite a 41% revenue jump, underscoring that the consolidated profit uplift is disproportionately coming from subsidiaries rather than the parent entity.

  • W1

    Whether cost-of-materials growth (+64.8% YoY this quarter) moderates relative to revenue growth (+45.7% YoY) — key to NPM recovering toward last year's 5.20%

  • W2

    Appropriation/quantum of the ~USD 7 million US customs-duty refund received in July 2026, pending finalisation per the company's note

  • W3

    Petcare segment loss trend (₹14.84 Cr this quarter vs ₹10.63 Cr YoY) against its 70% YoY revenue growth — whether scale starts converting to profitability

Both statements tie out exactly (totalIncome, PBT-tax=PAT). No exceptional items this quarter or in the year-ago quarter (Q4FY26 alone carried a ₹7.20 Cr one-off Netherlands provision, so YoY needs no adjustment). One unreviewed subsidiary contributed ₹145.91 Cr revenue/₹14.05 Cr PAT to consol; five smaller unreviewed subsidiaries add ₹32.55 Cr revenue/₹2.79 Cr PAT — both immaterial per auditor.

Informational and educational content only. Not investment advice.